The biopharmaceutical sector continues to experience significant workforce reductions, with 62 layoff rounds reported in Q3 2025, nearly matching the earlier quarters. Notable cuts include Novo Nordisk's 9,000 job reductions targeting annual savings of $1.3 billion, Merck & Co.’s plan to cut 6,000 positions as part of a $3 billion cost-saving program, and Sarepta Therapeutics’ 500-person downsizing linked to a strategic pipeline pivot and regulatory challenges. These restructuring efforts reflect ongoing financial pressures and strategic realignments within the industry.